RU2769871C2 - Поливалентные модуляторы регуляторных t-клеток - Google Patents

Поливалентные модуляторы регуляторных t-клеток Download PDF

Info

Publication number
RU2769871C2
RU2769871C2 RU2019121902A RU2019121902A RU2769871C2 RU 2769871 C2 RU2769871 C2 RU 2769871C2 RU 2019121902 A RU2019121902 A RU 2019121902A RU 2019121902 A RU2019121902 A RU 2019121902A RU 2769871 C2 RU2769871 C2 RU 2769871C2
Authority
RU
Russia
Prior art keywords
protein
leu
seq
ser
lys
Prior art date
Application number
RU2019121902A
Other languages
English (en)
Russian (ru)
Other versions
RU2019121902A (ru
RU2019121902A3 (enExample
Inventor
Джеффри Грив
Чонмин КИМ
Ниранджана НАГАРАДЖАН
Джон ЧО
Original Assignee
Делиниа, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Делиниа, Инк. filed Critical Делиниа, Инк.
Publication of RU2019121902A publication Critical patent/RU2019121902A/ru
Publication of RU2019121902A3 publication Critical patent/RU2019121902A3/ru
Application granted granted Critical
Publication of RU2769871C2 publication Critical patent/RU2769871C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/55—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
RU2019121902A 2016-12-13 2017-12-13 Поливалентные модуляторы регуляторных t-клеток RU2769871C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662433533P 2016-12-13 2016-12-13
US62/433,533 2016-12-13
PCT/US2017/066163 WO2018112069A1 (en) 2016-12-13 2017-12-13 Multivalent regulatory t cell modulators

Publications (3)

Publication Number Publication Date
RU2019121902A RU2019121902A (ru) 2021-01-18
RU2019121902A3 RU2019121902A3 (enExample) 2021-04-21
RU2769871C2 true RU2769871C2 (ru) 2022-04-07

Family

ID=62488540

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2019121902A RU2769871C2 (ru) 2016-12-13 2017-12-13 Поливалентные модуляторы регуляторных t-клеток

Country Status (11)

Country Link
US (2) US10472405B2 (enExample)
EP (1) EP3554525A4 (enExample)
JP (1) JP7228515B2 (enExample)
KR (1) KR20190094222A (enExample)
CN (1) CN110177564A (enExample)
AU (1) AU2017378308A1 (enExample)
BR (2) BR112019011799B1 (enExample)
CA (1) CA3044416A1 (enExample)
MX (2) MX381276B (enExample)
RU (1) RU2769871C2 (enExample)
WO (1) WO2018112069A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840545B2 (en) 2013-09-20 2017-12-12 University Of Virginia Patent Foundation Fusion protein comprising interleukin-2 and interleukin-33
CN110177564A (zh) 2016-12-13 2019-08-27 德里尼亚公司 多价的调节t细胞调节剂
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
AU2018273914A1 (en) 2017-05-24 2019-11-14 Pandion Operations, Inc. Targeted immunotolerance
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
KR20210055694A (ko) 2018-08-06 2021-05-17 메디카인 인코포레이티드 Il-2 수용체 결합 화합물
SG11202104120VA (en) * 2018-10-31 2021-05-28 Delinia Inc Multivalent regulatory t cell modulators
AU2020279240A1 (en) 2019-05-20 2021-12-23 Pandion Operations, Inc. MAdCAM targeted immunotolerance
JP2022536581A (ja) * 2019-06-19 2022-08-18 キュー バイオファーマ， インコーポレイテッド 多量体ｔ細胞調節性ポリペプチド及びその使用方法
CN110642934B (zh) * 2019-09-10 2022-08-23 中国医学科学院北京协和医院 靶向调节t细胞的长效白介素-2及其在治疗自身免疫病中的应用
CA3160466A1 (en) 2019-11-05 2021-05-14 Medikine, Inc. Dual il-2r and il-7r binding compounds
MX2022005411A (es) 2019-11-05 2022-08-10 Medikine Inc COMPUESTOS DE UNIÓN A IL-2RßYC.
AU2021217959A1 (en) 2020-02-03 2022-08-18 Medikine, Inc. IL-7Rα binding compounds
US11746139B2 (en) 2020-02-03 2023-09-05 Medikine, Inc. IL-7Rαγc binding compounds
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
US11999771B2 (en) 2022-04-07 2024-06-04 Medikine, Inc. IL-7Rαγc ligand immunoglobulin fusion proteins
WO2023220692A1 (en) * 2022-05-11 2023-11-16 Slate Bio, Inc. Compositions comprising truncated interleukin-33 and interleukin-2
AU2024381770A1 (en) * 2023-11-15 2026-05-28 Slate Bio, Inc. Bifunctional il-2 and il-33 proteins for treating autoimmune disease

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2235729C2 (ru) * 1998-05-15 2004-09-10 Байер Корпорейшн Селективные агонисты и антагонисты il-2
WO2014082179A1 (en) * 2012-11-28 2014-06-05 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US20160304574A1 (en) * 2013-09-20 2016-10-20 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
ATE407697T1 (de) 1999-07-13 2008-09-15 Bolder Biotechnology Inc Erythropoietin immunglobulin fusionsproteine
RU2006113701A (ru) 2003-09-23 2007-11-10 Пдл Байофарма, Инк. (Us) Лечение респираторных заболеваний антителами против рецептора il-2
AR091069A1 (es) * 2012-05-18 2014-12-30 Amgen Inc Proteinas de union a antigeno dirigidas contra el receptor st2
BR112015000798A2 (pt) * 2012-07-13 2017-06-27 Zymeworks Inc heterodímeros assimétricos biespecíficos compreendendo construtos anti-cd3
EP3421495A3 (en) * 2013-03-15 2019-05-15 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
PT3102595T (pt) * 2014-02-06 2019-01-11 Hoffmann La Roche Proteínas de fusão de interleucina-2 e suas utilizações
KR102493543B1 (ko) * 2014-07-21 2023-01-30 데리니아, 인크. 자가면역 질환의 치료를 위한 조절 t 세포를 선택적으로 활성화시키는 분자
CN110177564A (zh) 2016-12-13 2019-08-27 德里尼亚公司 多价的调节t细胞调节剂

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2235729C2 (ru) * 1998-05-15 2004-09-10 Байер Корпорейшн Селективные агонисты и антагонисты il-2
WO2014082179A1 (en) * 2012-11-28 2014-06-05 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
US20160304574A1 (en) * 2013-09-20 2016-10-20 University Of Virginia Patent Foundation Compositions and methods for treatment of autoimmune and inflammatory diseases and disorders

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
BENJAMIN W. U. et al., Pharmacokinetics of peptide-Fc fusion proteins, Journal of pharmaceutical sciences, 2014, V. 103, N. 1, p.53-64. *
CHEN X. et al., Fusion protein linkers: property, design and functionality, Advanced drug delivery reviews, 2013, v. 65, n. 10, p.1357-1369. *
JI-HEE HA ET AL., Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins, FRONTIERS IN IMMUNOLOGY, 2016, v.7, p.1 - 16. *
KONTERMANN R. E. et al., Bispecific antibodies, Drug Discovery Today, 2015, V. 7, N. 20, p.838-847. *
KONTERMANN R. E. et al., Bispecific antibodies, Drug Discovery Today, 2015, V. 7, N. 20, p.838-847. SHEN J. et al., Single variable domain-IgG fusion: a novel recombinant approach to Fc domain-containing bispecific antibodies, Journal of Biological Chemistry, 2006, V. 281, N. 16, p.10706-10714. SUZUKI T. et al., Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR, The journal of immunology, 2010, V. 184, N. 4, p.1968-1976. BENJAMIN W. U. et al., Pharmacokinetics of peptide-Fc fusion proteins, Journal of pharmaceutical sciences, 2014, V. 103, N. 1, p.53-64. CHEN X. et al., Fusion protein linkers: property, design and functionality, Advanced drug delivery reviews, 2013, v. 65, n. 10, p.1357-1369. MAEDA Y. et al., Engineering of functional chimeric protein G-Vargula Luciferase, Analytical biochemistry, 1997, v. 2 *
MAEDA Y. et al., Engineering of functional chimeric protein G-Vargula Luciferase, Analytical biochemistry, 1997, v. 249, n. 2, p.147-152. *
MULLER S. et al., Spliceosomal peptide P140 for immunotherapy of systemic lupus erythematosus: results of an early phase II clinical trial, Arthritis & Rheumatism: Official Journal of the American College of Rheumatology, 2008, V. 58, N. 12, p.3873-3883. *
SHEN J. et al., Single variable domain-IgG fusion: a novel recombinant approach to Fc domain-containing bispecific antibodies, Journal of Biological Chemistry, 2006, V. 281, N. 16, p.10706-10714. *
SUZUKI T. et al., Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR, The journal of immunology, 2010, V. 184, N. 4, p.1968-1976. *
THOMAS SPRETER VON KREUDENSTEIN ET AL., Improving biophysical properties of a bispecific antibody scaffold to aid developability : Quality by molecular design, MABS, 2013, v. 5, n. 5, p. 646 - 654. *
ZHENG X. X. ET AL., IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice, THE JOURNAL OF IMMUNOLOGY, 1999, v. 163, n. 7, p. 4041 - 4048. *
ZHENG X. X. ET AL., IL-2 receptor-targeted cytolytic IL-2/Fc fusion protein treatment blocks diabetogenic autoimmunity in nonobese diabetic mice, THE JOURNAL OF IMMUNOLOGY, 1999, v. 163, n. 7, p. 4041 - 4048. JI-HEE HA ET AL., Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins, FRONTIERS IN IMMUNOLOGY, 2016, v.7, p.1 - 16. *

Also Published As

Publication number Publication date
EP3554525A4 (en) 2020-08-19
MX381276B (es) 2025-03-12
AU2017378308A1 (en) 2019-06-20
BR112019011799B1 (pt) 2021-12-21
EP3554525A1 (en) 2019-10-23
JP2020501550A (ja) 2020-01-23
US20180162919A1 (en) 2018-06-14
WO2018112069A1 (en) 2018-06-21
RU2019121902A (ru) 2021-01-18
RU2019121902A3 (enExample) 2021-04-21
US20200031897A1 (en) 2020-01-30
KR20190094222A (ko) 2019-08-12
CA3044416A1 (en) 2018-06-21
CN110177564A (zh) 2019-08-27
MX2021004007A (es) 2021-06-23
US10472405B2 (en) 2019-11-12
JP7228515B2 (ja) 2023-02-24
MX2019007002A (es) 2019-08-22
US11059877B2 (en) 2021-07-13
BR112019011799A2 (pt) 2019-10-29
BR122020025384B1 (pt) 2022-07-12

Similar Documents

Publication Publication Date Title
US11059877B2 (en) Multivalent regulatory T cell modulators
US20210403579A1 (en) Multivalent regulatory t cell modulators
CN114901679B (zh) 全新被掩蔽的细胞因子及其应用
US20030223989A1 (en) CD137 agonists to treat patients with IgE-mediated conditions
JP7644151B2 (ja) 抗ｐｄ－１抗体および融合タンパク質
CA3194384A1 (en) Caninized rat antibodies to canine interleukin-31 receptor alpha
JP6943885B2 (ja) 投与量レジメンデザインに関する材料および方法
JP2024526080A (ja) インターロイキン１５多様体
US20250122285A1 (en) Interleukin-2 muteins, fusion proteins, pharmaceutical compositions, and therapeutic applications
US20250368738A1 (en) Anti-cd28 antibodies
US20240150483A1 (en) COMPOSITIONS COMPRISING 4-1BB and OX40 BINDING PROTEINS AND METHODS OF USE
RU2854627C1 (ru) Биспецифические канинизированные антитела для лечения атопического дерматита
HK40052681A (en) Multivalent regulatory t cell modulators
HK40008615A (en) Multivalent regulatory t cell modulators
US20230285555A1 (en) Preparation specifically bound with cd137 and use thereof
EA039118B1 (ru) Способ лечения прогрессирующей оссифицирующей фибродисплазии